WallStreetZenWallStreetZen

NASDAQ: ANL
Adlai Nortye Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ANL

Based on 2 analysts offering 12 month price targets for Adlai Nortye Ltd

Min Forecast
$20.00+73.01%
Avg Forecast
$21.00+81.66%
Max Forecast
$22.00+90.31%

Should I buy or sell ANL stock?

Based on 2 analysts offering ratings for Adlai Nortye Ltd.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ANL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ANL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ANL stock forecasts and price targets.

ANL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-04-20

1 of 1

Forecast return on equity

Is ANL forecast to generate an efficient return?

Forecast return on assets

Is ANL forecast to generate an efficient return on assets?

Company
-439.99%
Industry
29.42%
ANL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ANL earnings per share forecast

What is ANL's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.23
Avg 2 year Forecast
-$0.32
Avg 3 year Forecast
-$0.50

ANL revenue forecast

What is ANL's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$5.2M+3.52%
Avg 2 year Forecast
$168.3k-96.63%
Avg 3 year Forecast
$13.6M+172.7%
ANL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ANL revenue growth forecast

How is ANL forecast to perform vs Biotechnology companies and vs the US market?

Company
27.85%
Industry
36.05%
Market
13.75%
ANL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ANL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ANL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ANL$11.56$21.00+81.66%Strong Buy
UPB$8.46$32.50+284.16%Buy
OCGN$1.35$9.75+622.22%Strong Buy
STTK$6.09$12.75+109.36%Buy
OVID$2.44$4.50+84.43%Strong Buy
View Top Biotech Stocks

Adlai Nortye Stock Forecast FAQ

Is Adlai Nortye Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ANL) stock is to Strong Buy ANL stock.

Out of 2 analysts, 1 (50%) are recommending ANL as a Strong Buy, 1 (50%) are recommending ANL as a Buy, 0 (0%) are recommending ANL as a Hold, 0 (0%) are recommending ANL as a Sell, and 0 (0%) are recommending ANL as a Strong Sell.

If you're new to stock investing, here's how to buy Adlai Nortye stock.

What is ANL's earnings growth forecast for 2026-2028?

(NASDAQ: ANL) Adlai Nortye's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Adlai Nortye's earnings in 2026 is -$35,528,000.On average, 5 Wall Street analysts forecast ANL's earnings for 2026 to be -$27,276,183, with the lowest ANL earnings forecast at -$31,752,212, and the highest ANL earnings forecast at -$22,680,152. On average, 4 Wall Street analysts forecast ANL's earnings for 2027 to be -$37,980,254, with the lowest ANL earnings forecast at -$50,568,338, and the highest ANL earnings forecast at -$31,500,211.

In 2028, ANL is forecast to generate -$60,192,403 in earnings, with the lowest earnings forecast at -$105,840,708 and the highest earnings forecast at -$36,540,245.

What is ANL's revenue growth forecast for 2026-2028?

(NASDAQ: ANL) Adlai Nortye's forecast annual revenue growth rate of 27.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Adlai Nortye's revenue in 2026 is $5,000,000.On average, 5 Wall Street analysts forecast ANL's revenue for 2026 to be $621,124,156, with the lowest ANL revenue forecast at $0, and the highest ANL revenue forecast at $2,520,016,863. On average, 4 Wall Street analysts forecast ANL's revenue for 2027 to be $20,200,575, with the lowest ANL revenue forecast at $0, and the highest ANL revenue forecast at $37,800,253.

In 2028, ANL is forecast to generate $1,636,210,949 in revenue, with the lowest revenue forecast at $23,520,157 and the highest revenue forecast at $5,040,033,726.

What is ANL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ANL) forecast ROA is -439.99%, which is lower than the forecast US Biotechnology industry average of 29.42%.

What is ANL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ANL price target, the average ANL price target is $21.00, with the highest ANL stock price forecast at $22.00 and the lowest ANL stock price forecast at $20.00.

On average, Wall Street analysts predict that Adlai Nortye's share price could reach $21.00 by May 14, 2027. The average Adlai Nortye stock price prediction forecasts a potential upside of 81.66% from the current ANL share price of $11.56.

What is ANL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ANL) Adlai Nortye's current Earnings Per Share (EPS) is -$1.11. On average, analysts forecast that ANL's EPS will be -$0.23 for 2026, with the lowest EPS forecast at -$0.26, and the highest EPS forecast at -$0.19. On average, analysts forecast that ANL's EPS will be -$0.32 for 2027, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at -$0.26. In 2028, ANL's EPS is forecast to hit -$0.50 (min: -$0.88, max: -$0.30).

What is ANL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ANL) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.